About CeQur
CeQur is a company based in Horw (Switzerland) founded in 2008. CeQur has raised $391.6 million across 5 funding rounds from investors including Tandem Diabetes, Credit Suisse and Schroders. CeQur offers products and services including CeQur Simplicity Patch. CeQur operates in a competitive market with competitors including scPharmaceuticals, Crossject, Valeritas, Vaxxas and Incline Therapeutics, among others.
- Headquarter Horw, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cequr Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$391.6 M (USD)
in 5 rounds
-
Latest Funding Round
$120 M (USD), Series D
Jan 07, 2025
-
Investors
Tandem Diabetes
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CeQur
CeQur offers a comprehensive portfolio of products and services, including CeQur Simplicity Patch.
Wearable patch for injection-free insulin delivery and glucose management.
Funding Insights of CeQur
CeQur has successfully raised a total of $391.6M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $120 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CeQur
CeQur has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Tandem Diabetes, Credit Suisse and Schroders.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Endeavour Vision is focused on transformative healthcare technology investments.
|
Locked | Locked | Locked | |
|
Early-stage venture capital is invested in US and Europe.
|
Locked | Locked | Locked |
Investor details for CeQur
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CeQur
Investment portfolio details for CeQur
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CeQur
Detailed financials for CeQur
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cequr Comparisons
Peer comparison for CeQur
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CeQur
CeQur operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as scPharmaceuticals, Crossject, Valeritas, Vaxxas and Incline Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| Locked | Locked | Locked |
Needle-free self-injectable drugs
|
|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| Locked | Locked | Locked |
Developer of vaccines to treat cancer and infectious diseases
|
|
| Locked | Locked | Locked |
Hospital-focused specialty pharmaceuticals are developed for acute pain management.
|
Detailed competitors of CeQur
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cequr
Complete news archive for CeQur
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CeQur
CeQur was founded in 2008 and raised its 1st funding round 2 years after it was founded.
CeQur is headquartered in Horw, Switzerland. It is registered at Horw, Luzern, Switzerland.
Bradley Paddock is the current CEO of CeQur.
CeQur is a funded company, having raised a total of $391.6M across 5 funding rounds to date.
CeQur was founded in 2008 and is headquartered in Horw, Switzerland. Operations focus on the medical device sector, particularly diabetes management solutions. The CeQur Simplicity device, a 3-day wearable patch, is designed to deliver rapid-acting insulin subcutaneously via a built-in cannula. This enables injection-free administration of mealtime boluses under the skin for users requiring insulin therapy.
CeQur's top competitors include scPharmaceuticals, Crossject and Vaxxas.
CeQur offers CeQur Simplicity Patch.
CeQur has 9 investors. Key investors include Tandem Diabetes, Credit Suisse, Schroders, Ypsomed, and Woodford Investment Management.